About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Liraglutide [Victoza]
- Company
- Turku University Hospital
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- None currently listed
Efficacy results: Not yet reported
No recruiting studies currently listed
See all studies for this drugData source: ClinicalTrials.gov · trial data as of Oct 24, 2026
Trial details
-
Completed NCT NCT01399645
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
Not yet reported Centre hospitalier de l'Université de Montréal (CHUM) 35 participants Est. completion 2014-06 1 siteMASLDMASHType 2 diabetesView official trial listing → -
Completed NCT NCT01460069
The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis
Not yet reported Annesofie Faurschou 20 participants Est. completion 2013-05 1 siteOther conditions: PsoriasisView official trial listing → -
Completed NCT NCT01469351
Identifying Potential Effects of Liraglutide on Degenerative Changes
Not yet reported University of Aarhus 34 participants Est. completion 2013-04 1 siteOther conditions: Alzheimers DiseaseView official trial listing → -
Completed NCT NCT01550653
Liraglutide Effects on Memory in Healthy Subjects
Not yet reported University of Luebeck 40 participants Est. completion 2013-12 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT01676116
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
Not yet reported Novo Nordisk A/S 438 participants Est. completion 2014-03-11 109 sitesType 2 diabetes Other conditions: DiabetesView official trial listing → -
Completed NCT NCT01687582
Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients
Not yet reported Cliniques universitaires Saint-Luc- Université Catholique de Louvain 10 participants Est. completion 2013-03 1 siteType 2 diabetes Other conditions: PsoriasisView official trial listing → -
Completed NCT NCT01740921
GLP-1 and Microvascular Function in Type 2 Diabetes
Not yet reported Royal Devon and Exeter NHS Foundation Trust 39 participants Est. completion 2016-02 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT01821846
Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S 64 participants Est. completion 2017-03-08 7 sitesType 2 diabetes Other conditions: DiabetesView official trial listing → -
Terminated NCT NCT01934816
Incretin and KATP Channels
Not yet reported Katarina Kos 2 participants Est. completion 2015-10 1 siteOther conditions: Healthy SubjectsView official trial listing → -
Completed NCT NCT02014740
Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes
Not yet reported University of Miami 100 participants Est. completion 2017-03 1 siteType 2 diabetes Other conditions: Overweight, ObesityView official trial listing → -
Completed NCT NCT02043054
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)
Not yet reported University of Leicester 90 participants Est. completion 2017-09-29 1 siteType 2 diabetesCardiovascular diseaseView official trial listing → -
Withdrawn NCT NCT02198209
Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation
Not yet reported Cedars-Sinai Medical Center Est. completion 2020-12 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02201550
Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide
Hvidovre University Hospital 9 participants Est. completion 2014-04 1 siteType 2 diabetesView official trial listing → -
Terminated NCT NCT02244164
Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.
Not yet reported Erasme University Hospital 5 participants Est. completion 2023-02-13 1 siteType 2 diabetes Other conditions: Incretinomimetics, PancreasView official trial listing → -
Completed NCT NCT02321878
Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)
Novo Nordisk A/S 1092 participants Est. completion 2017-06-16 5 sitesType 2 diabetes Other conditions: DiabetesView official trial listing → -
Completed NCT NCT02473809
The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function
Not yet reported University of Aarhus 60 participants Est. completion 2017-10 1 siteOther conditions: Diabetes Complications, OsteoporosisView official trial listing → -
Completed NCT NCT02650206
Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood
Not yet reported Stanford University 56 participants Est. completion 2019-09-27 1 siteType 2 diabetes Other conditions: Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, InflammationView official trial listing → -
Completed NCT NCT03010683
Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus
Not yet reported University of Athens 60 participants Est. completion 2017-12 1 siteType 2 diabetesCardiovascular diseaseView official trial listing → -
Status unknown NCT NCT03421119
Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes
Not yet reported Cinnagen 300 participants Est. completion 2019-12-01Type 2 diabetesView official trial listing → -
Completed NCT NCT04324229
Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes
Not yet reported Turku University Hospital 67 participants Est. completion 2025-04-09 1 siteOther conditions: Gestational DiabetesView official trial listing → -
Active, not recruiting NCT NCT07325435
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Not yet reported MaryAnn Banerji 60 participants Est. completion 2028-06-30 1 siteType 2 diabetesView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: Liraglutide [Victoza], Liraglutide 6 MG/ML [Victoza]
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.